Sevelamer carbonate is a phosphate-binding medication prescribed to people with chronic kidney disease (CKD) who are on dialysis. When the kidneys can no longer filter phosphorus from the blood effectively, phosphorus levels climb and can damage bones, blood vessels, and the heart. Sevelamer carbonate works in the gut, not the bloodstream: it binds to phosphorus from food during digestion and carries it out of the body in stool, preventing it from ever reaching the blood.
Why Phosphorus Control Matters in Kidney Disease
Healthy kidneys filter excess phosphorus constantly. In advanced CKD, that filtration slows or stops, and phosphorus accumulates. High blood phosphorus pulls calcium from bones, weakens the skeleton, and deposits calcium-phosphorus crystals in arteries and soft tissues. Over time this accelerates cardiovascular disease, which is already the leading cause of death in dialysis patients. Dialysis itself removes some phosphorus, but not enough. Diet alone rarely keeps levels in check either. That gap is where phosphate binders like sevelamer carbonate come in.
How It Works
Sevelamer carbonate is a large polymer, essentially a plastic-like molecule that passes through the digestive tract without being absorbed. When you take it with a meal, it chemically grabs onto phosphate molecules released during digestion. The bound phosphorus can no longer cross from the intestine into the bloodstream, so it’s eliminated when you have a bowel movement. Because the drug never enters your blood, its effects are almost entirely limited to the gut.
The “carbonate” part of the name matters. An older version, sevelamer hydrochloride, uses the same phosphate-binding polymer but releases chloride instead of carbonate. That chloride load lowered bicarbonate levels in the blood and raised the risk of metabolic acidosis, a condition where the blood becomes too acidic. Sevelamer carbonate was specifically reformulated to avoid this problem. Studies in hemodialysis and peritoneal dialysis patients found that the carbonate version does not decrease serum bicarbonate levels, making it a better fit for people already at risk for acidosis.
Who Takes It
The FDA has approved sevelamer carbonate (brand name Renvela) for controlling serum phosphorus in adults and children aged 6 and older with CKD who are on dialysis. It is not typically used in earlier stages of kidney disease or in people with normal kidney function. Because it contains no calcium, aluminum, or other metals, it’s often preferred over calcium-based phosphate binders in patients who already have high calcium levels or vascular calcification.
Available Forms
Sevelamer carbonate comes as tablets and as a powder for oral suspension. The powder is available in 0.8 g and 2.4 g pouches. To prepare the powder, you mix it into water (at least 1 ounce for the 0.8 g pouch or 2 ounces for the 2.4 g pouch), stir vigorously, and drink the entire mixture within 30 minutes. It won’t fully dissolve, so you may need to re-stir right before drinking. The powder can also be mixed into a small amount of food or a cold beverage and consumed with a meal. You should never heat the powder or add it to hot foods or liquids, as heat can alter the medication.
How It’s Dosed
Dosing is based on your blood phosphorus level. If you haven’t taken a phosphate binder before, the typical starting doses look like this:
- Phosphorus 5.5 to 7.5 mg/dL: 800 mg three times daily with meals
- Phosphorus 7.5 to 9 mg/dL: 1,200 to 1,600 mg three times daily with meals
- Phosphorus above 9 mg/dL: 1,600 mg three times daily with meals
The goal is to bring phosphorus to 5.5 mg/dL or lower. Your dose gets adjusted every two weeks in increments of 400 to 800 mg per meal until you reach that target. If phosphorus drops below 3.5 mg/dL, the dose is reduced. Regular blood work guides these adjustments, so expect frequent lab draws, especially in the first few months.
Common Side Effects
Because sevelamer carbonate acts in the gut, most side effects are digestive. In a short-term clinical study of the carbonate formulation, nausea and vomiting each occurred in about 3% of patients. Longer-term data from the older hydrochloride version (which uses the same active molecule) showed higher rates: vomiting in 22%, nausea in 20%, diarrhea in 19%, indigestion in 16%, abdominal pain in 9%, gas in 8%, and constipation in 8%. The carbonate form appears better tolerated overall, but gut symptoms remain the most frequent complaint.
Constipation deserves special attention. If it develops or worsens, it’s important to address it promptly because untreated constipation on sevelamer can, in rare cases, lead to fecal impaction, bowel obstruction, or intestinal perforation. Skin reactions like itching and rash have also been reported after the drug entered wide use.
Interactions With Other Medications
Sevelamer doesn’t just bind phosphorus. It can also grab onto certain medications in the gut and reduce how much your body absorbs. Thyroid hormone replacement is a well-documented example: in reported cases, sevelamer carbonate markedly reduced absorption, and patients needed to separate the two doses by at least four hours to restore normal thyroid levels. Certain antibiotics and immune-suppressing drugs can also be affected. The general rule is to take other medications either well before or well after sevelamer, and to let your prescriber know everything you’re taking so timing can be coordinated.
The Carbonate Advantage Over Hydrochloride
Both forms of sevelamer control phosphorus equally well. The key difference is what happens to acid-base balance. Sevelamer hydrochloride consistently lowered bicarbonate levels in clinical studies, pushing patients toward metabolic acidosis. For dialysis patients who already struggle with acid buildup due to poor kidney function, that added risk was unwelcome. Sevelamer carbonate was designed to release carbonate instead of chloride, effectively neutralizing that acid load. For patients at risk for or already experiencing metabolic acidosis, the carbonate formulation is the more appropriate choice, and it has largely replaced the hydrochloride version in clinical practice.